Vision & Mission

Sera Prognostics aims to be a global leader in high-value women’s health diagnostics, delivering pivotal information to physicians to improve the health of pregnant women and newborns, and to simultaneously improve the economics.



We are dedicated to improving the health of mothers and babies by ensuring that everything we do is of the highest standards and rigor.


We are not satisfied with the status quo. We seek to change it through novel approaches fueled by our motivation to address adverse conditions affecting pregnancy.


We prize the strength of the collective. We value the contribution that diversity brings through people, ideas, and approaches.


We actively seek to understand root causes for pregnancy complications and work to address them in all aspects of our business.


We value honesty and clarity. We stand behind our commitments.


We take responsibility for our actions, both individually and collectively


We work tirelessly and relentlessly to achieve our goals.

Company History

  • 2008

Scientists at the University of Utah and Brigham Young University conducted early discovery activities for proteomic prediction of preterm delivery. A local seed investor licensed the discoveries from the Universities and formed Sera Prognostics.

  • 2010
Greg Critchfield, MD, MS was recruited to Sera’s Board and began transforming the company strategy and securing funding
  • 2011

First large institutional venture capital funding was secured, enabling the launch of the landmark PAPR study to discover, develop and validate the PreTRM® Test

  • 2016

Published broad U.S. validation of preterm birth risk prediction in the PAPR Study, in the American Journal of Obstetrics and Gynecology. Science recognized as highest quality and importance by AJOG Editor’s Choice award

  • 2017

Sera’s developmental pipeline expands to cover a number of important pregnancy conditions to enable Sera to become The Pregnancy Company®

  • 2018

Three prospective controlled intervention studies initiated, TREETOP, PREVENT-PTB & AVERT PRETERM TRIAL

  • 2019

Data-driven commercialization strategy developed in collaboration with the maternal-fetal medicine community providing the foundation to secure widespread payer coverage

  • 2020

Release of positive top-line prospective intervention data from PREVENT-PTB study Society for Reproductive Investigation

  • 2020

Prospective randomized controlled PRIME trial launched within Anthem network

  • 2021

Sera completes $100 million series E financing

  • 2020

Sera and Anthem announce partnership for commercial testing within Anthem network.

  • 2020

Published the results of a prospective, randomized controlled intervention trial, PREVENT-PTB. The study demonstrates the positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare

Our Commitment

Sera Prognostics, Inc. is an organization with strong values of responsibility and integrity. Our Code of Conduct contains general guidelines for conducting business with the highest standards of ethics.

Sera is committed to an environment where open, honest communications are the expectation, not the exception. We want concerned individuals to feel comfortable in approaching the company about potential violations of policies, standards, laws or regulations.

Scroll to Top